Table 1 Patient demographic data and clinical characteristics of responding group and nonresponding group
RG(n = 36) | NRG(n = 20) | t/χ2 | p | |
|---|---|---|---|---|
Age | 43.75 ± 13.14 | 48.75 ± 11.92 | 1.41 | 0.165 |
Gender | 0.003 | 0.959 | ||
Male | 29 (80.6%) | 17 (85.0%) | ||
Female | 7 (19.4%) | 3 (15.0%) | ||
AJCC T stage | 2.716 | 0.444 | ||
T1 | 2 (5.6%) | 0 (0%) | ||
T2 | 18 (50.0%) | 7 (35.0%) | ||
T3 | 10 (27.8%) | 7 (35.0%) | ||
T4 | 6 (16.7%) | 6 (30.0%) | ||
A CC N stage | 2.869 | 0.406 | ||
N0 | 1 (2.8%) | 1 (5.0%) | ||
N1 | 5 (13.9%) | 6 (30.0%) | ||
N2 | 16 (44.4%) | 6 (30.0%) | ||
N3 | 14 (38.9%) | 7 (35.0%) | ||
Pathological classification | 3.283 | 0.224 | ||
non-cornification undifferentiated | 19 (52.8%) | 7 (35.0%) | ||
low differentiated | 15 (41.7%) | 9 (45.0%) | ||
moderately differentiated | 2 (5.6%) | 4 (20.0%) | ||
IC regimes | 1.344 | 0.246 | ||
Docetaxel + Cisplatin | 27 (75%) | 12 (60%) | ||
Paclitaxel-albumin + Cisplatin | 9 (25%) | 8 (40%) |